Cytek Biosciences, Inc.
CTKBHealthcareNASDAQMedical Devices · Last scanned May 29, 2026
Scan Results
Daily timeframePart of the healthcare sector, Cytek Biosciences, Inc. (CTKB) is listed under Medical Devices. At a $532.1M market cap, Cytek Biosciences, Inc. ranks as a small-cap company within healthcare. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems.
Market Cap
$532.1M
Beta
1.23
P/E (TTM)
—
P/E (Fwd)
21.68
EPS (TTM)
$-0.58
EPS (Fwd)
$0.19
ROE
-20.9%
ROA
-5.9%
Cash
$262.2M
Total Debt
$27.5M
Free CF
$6.4M
52W Change
48.7%
Annual Financials
Cash vs Debt
With $262.2M in cash and $27.5M in debt, CTKB maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $6.4M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -20.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $164.0M (2022) to $201.5M (2025), reflecting a 23% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Cytek Biosciences, Inc.'s trajectory.